Catalent Cell and Gene Content
-
Process Validation: A Critical Step In A Biopharma Product's Lifecycle
7/26/2023
Process validation is a critical step in the successful commercialization of a new biopharmaceutical. Learn about the challenges and the importance of applying it throughout the entire product lifecycle.
-
Cell & Gene Therapies – Changing The Healthcare Landscape
7/20/2023
Experts discuss how cell & gene therapies are changing the healthcare landscape and what needs to be done to bring these advanced therapies to patients.
-
07.14.23 -- Accelerate Development Timelines With Improved Characterization Methods
7/14/2023
07/14/23 Life Science Leader Newsletter
-
Exploring An Integrated Solution For AAV Vector Clinical Production
Every choice is critical in AAV vector production. Experts share how to make the right choices, from the process and cell line, to off-the-shelf plasmids and qualified analytical methods.
-
Innovations In ADC Technologies
Examine the drivers behind the recent successes in the clinic, current challenges with development and manufacturing, and what the future might hold for the ADC industry.
-
UpTempo℠ AAV Platform Process
Catalent’s UpTempo℠ AAV platform process is a scalable, cGMP-ready process for viral vector manufacturing that can reduce the current 18-20-month development timeline for drug product in half.
-
Plasmid DNA And Advanced Therapies: Accelerating Path To Clinic
Examine the challenges CGT innovators face and how adhering to GMP requirements from an early stage helps to ensure successful downstream applications from early clinical development to commercial phase.
-
Harnessing mRNA As A Readout To Develop Robust BioPotency Assays
Discover a new potency bioassay using RT-qPCR to assess relative transcription activity, and learn more about the advantages and limitations of transcriptional assays versus reporter gene assays.
-
Process Optimization For mAb Commercial Manufacturing
Strategically optimize your upstream and downstream processes and decrease the timeline from optimization to commercial manufacturing.
-
Accelerating Your Gene Therapy: Not All Platforms Are Created Equal
Standardized methods, materials, and analytics are critical for overcoming hurdles in the gene therapy space. Explore how a platform approach to fast-track AAVs can enhance quality and efficiency.